Independent and not affiliated with the FDA, MHRA, ISPE, PDA, or any agency. Get the appgoutham@madhadi.com
madhadi.comData Integrity & GxP Quality
Browse all topics → Articles Templates & Procedures Learning paths GlossaryScenariosToolsRegulatory ReferencesLearning PathsTopics About Start here
Protocol Plug-and-play starting point Equipment Qualification

Protocol: Analytical Method Transfer

A plug-and-play analytical method transfer protocol covering scope, transfer approach justification, sample and analytical plan, predefined acceptance criteria (TOST equivalence), deviation handling, and dual-site approval, with a filled specimen for a small-molecule assay transfer.

Document type: Protocol

Read and copy the template below into your own quality system. It is a generic starting point for your own internal use, provided as is, with no warranty; see the Terms and License. Adopting it does not by itself create compliance.

This is a ready-to-use protocol for transferring a validated analytical procedure from a sending unit (SU) to a receiving unit (RU). Acceptance criteria must be set here, before any testing, and never revised after the data is reviewed. Replace every <<FILL: ...>> placeholder, route it through dual-site QA approval, and confirm every cited regulation against the current source before you rely on it. This content is educational reference, not legal or regulatory advice.

Approval page

FieldEntry
Protocol titleAnalytical Method Transfer, <<FILL: method name>>
Protocol number<<FILL: PROTOCOL-ID>>
Version<<FILL>>
Sending unit (SU)<<FILL: site / lab>>
Receiving unit (RU)<<FILL: site / lab>>
Product / specification<<FILL>>

1. Objective

To demonstrate, through a predefined and dual-site-approved comparison, that <<FILL: RU name>> can execute <<FILL: method name and number>> and obtain results equivalent to <<FILL: SU name>>, so that the RU can be authorized to use the method for its intended GxP purpose.

2. Scope

This protocol applies to <<FILL: method name, number, version>> for <<FILL: product / specification>>, transferring from <<FILL: SU>> to <<FILL: RU>>. It does not cover other methods or other receiving sites; each requires its own protocol or a documented extension.

3. System description / method summary

Briefly describe the method (technique, what it measures, key instrumentation) and reference the controlling method document and validation report.

FieldEntry
Method document number and version<<FILL>>
Validation report reference<<FILL>>
Method type<<FILL: assay / related substances / dissolution / bioassay / microbiological / other>>

4. Prerequisites

  • Current, controlled method document issued to the RU (not a draft or marked-up copy).
  • RU instruments qualified and within calibration.
  • RU analysts trained on the method with documented competency.
  • Reference standards and reagents of the correct grade, lot, and in-date status available at the RU.
  • Sample material identified, with a plan for splitting and shipping if sites are in different locations.

See the paired readiness checklist for the pre-transfer gate.

5. Roles

RoleResponsibility
Protocol author<<FILL: name/role>>, defines approach, sample plan, and acceptance criteria
SU technical leadSupplies method documentation, standards, and technical oversight
RU technical leadExecutes RU testing, confirms readiness, owns the method after transfer
SU Quality AssuranceApproves protocol and report at the sending site
RU Quality AssuranceApproves protocol and report at the receiving site; gates start of routine release testing
Statistician / numerate reviewerSets or reviews the equivalence limit and statistical test

6. Transfer approach

FieldEntry
Approach selected<<FILL: Comparative testing / Co-validation / Revalidation at RU / Transfer waiver>>
Justification<<FILL: why this approach fits the situation>>

7. Sample and analytical plan

FieldEntry
Sample material / lot(s)<<FILL>>
Number of independent preparations per lab<<FILL>>
Concentrations / levels tested<<FILL: e.g. 100% nominal; near specification; near LOQ>>
Number of analysts at RU<<FILL: minimum 2 recommended>>
Number of instruments at RU<<FILL>>
Shipping / chain of custody plan (if applicable)<<FILL>>

8. Predefined acceptance criteria

State every criterion as a number, decided before testing. Do not leave any cell as a qualitative aspiration.

ParameterTestAcceptance criterion (predefined)
<<FILL: e.g. Assay accuracy/equivalence>><<FILL: e.g. n preps per lab, same lot>><<FILL: e.g. 90% CI of (RU mean minus SU mean) entirely within +/- X% (TOST)>>
<<FILL: e.g. RU precision>><<FILL>><<FILL: e.g. %RSD <= validated repeatability limit>>
<<FILL: e.g. related substances>><<FILL>><<FILL>>
<<FILL: e.g. system suitability>><<FILL: every run, both labs>><<FILL>>

9. Deviation and failure handling

  1. Any criterion not met is a transfer failure, investigated per section 10, not retested informally.
  2. Any deviation from the protocol (a substitution, a timing change, a missed step) is documented at the time it occurs, assessed for impact, and approved by both QA units before the affected data is used in the conclusion.
  3. Acceptance criteria are never revised after data review. A failed criterion is addressed by investigation and, where justified, a repeat of the affected portion under the same or an amended, re-approved protocol.

10. Acceptance criteria for the transfer overall

  • Every predefined criterion in section 8 is met, or the deviation is investigated to a documented assignable cause and the affected portion repeated and passed.
  • All system suitability requirements are met on the RU’s own equipment.
  • Raw data, calculations, and instrument outputs are complete and reconstructable by a reviewer who was not present.
  • The protocol was approved by both QA units before testing began.

11. References

USP General Chapter <1224>, Transfer of Analytical Procedures. USP General Chapter <1226>, Verification of Compendial Procedures (if a compendial method is involved). ICH Q2(R2), Validation of Analytical Procedures. FDA, Analytical Procedures and Methods Validation for Drugs and Biologics (2015). EU GMP Part I, Chapter 6 (Quality Control).

Confirm the current version and clause numbers of each reference before issue.

12. Approvals (before testing)

RoleNameSignatureDate
Protocol author<<FILL>>
SU Quality Assurance<<FILL>>
RU Quality Assurance<<FILL>>

Filled specimen

Excerpt of a completed protocol for an example small-molecule assay transfer. Illustrative only.

FieldEntry
MethodHPLC assay and related substances, tablet, method TM-0042 v2.0
SU / RUDevelopment QC Lab / Commercial QC Lab, Site B
Transfer approachComparative testing (Approach 1); both labs operational concurrently, same lot available
ParameterTestAcceptance criterion (predefined)
Assay accuracy/equivalence6 independent preps per lab, same lot90% CI of (RU mean - SU mean) entirely within +/-3.0% of label claim (TOST)
Assay precision (RU)6 preps, RU only%RSD <= 2.0%
Related substancesSpiked sample at specification levelRU within +/-25% relative of SU (or +/-0.05% absolute, whichever larger)
System suitabilityEvery run, both labsResolution >= 2.0; tailing <= 2.0; standard %RSD <= 1.0% (n=5)

Result: RU mean 100.8%, SU mean 99.6%, 90% CI of the difference 0.26% to 2.14%, entirely inside +/-3.0%. Assay criterion met. All other criteria met on first execution. Conclusion: transferred, no conditions.

Common inspection findings this protocol prevents

  • Acceptance criteria written as qualitative statements (“results should be comparable”) rather than predefined numbers.
  • A protocol approved after testing began, or approved by only one site’s QA.
  • The transfer approach selected with no documented justification for why it fits the situation.
  • No named minimum number of analysts or instruments at the RU, so the study proves the method works once, not that it works in the RU’s real operation.

How to adapt this protocol

  1. Set the method, sites, and product in the header.
  2. Select and justify the transfer approach in section 6 based on your actual situation (concurrent testing possible or not, multi-site design, waiver basis).
  3. Fill section 8 with real numeric criteria derived from the method’s validated repeatability and a stated equivalence limit; do not leave any criterion qualitative.
  4. Point section 9’s investigation process to your real deviation and OOS procedures.
  5. Confirm every regulation in section 11 against the current published version before issue.
Use madhadi.com as an app Full screen, works offline, one tap from your home screen.